Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held June 3-7, 2011 in Chicago, Illinois.  The data presentations at ASCO 2011 will highlight the anti-tumor activity of NKTR-102 in patients with metastatic breast cancer and platinum-resistant ovarian cancer. In addition, a separate presentation will be made on the population pharmacokinetics for NKTR-102.

"The NKTR-102 clinical data we will report at ASCO continue to support the robust clinical benefit and significant anti-tumor activity we have observed to date in our clinical studies with this promising anti-cancer agent," said Lorianne Masuoka, MD, Senior Vice President and Chief Medical Officer of Nektar.  "These findings strongly support our continued development of NKTR-102 in multiple tumor settings."